Ligand Pharmaceuticals signs deal possibly worth $75 million
Ligand Pharmaceuticals of La Jolla has licensed DARA to Retrophin, which will use the compounds to explore treatments for kidney disease. The agreement will net Ligand an upfront payment of $1 million and could lead to more than $75 million in milestone payments, and 9-percent in royalties, the company says.
DARA refers to dual-action receptor antagonists, which can help minimize organ damage caused by hypertension.
Sources: Gary Robbins, San Diego Union Tribune
Links to products related:
Sincerely, Chip Lindgren, Founder & President, AG Scientific, Inc.
************************************************************
AG Scientific, Inc., an ISO 9001:2008 Company
6450 Lusk Blvd. Ste. E102,
San Diego, CA 92121, Phone +858 452 9925,
Fax +858 452 9926, www.agscientific.com
Personal email: chip@agscientific.com
Corporate email: info@agscientific.com
************************************************************